Bluejay Diagnostics (BJDX) EBT (2020 - 2026)

Bluejay Diagnostics (BJDX) has 7 years of EBT data on file, last reported at -$2.0 million in Q1 2026.

• For the quarter ending Q1 2026, EBT fell 5.79% year-over-year to -$2.0 million; the trailing twelve-month figure through Mar 2026 stood at -$7.0 million (up 12.52% YoY), and the FY2025 full-year result was -$18.9 million, down 11.06% from the prior year.
• EBT fell to -$2.0 million in Q1 2026, from -$1.4 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$1.4 million in Q4 2025 to a low of -$3.0 million in Q2 2023.
• A 5-year average of -$2.2 million and a median of -$2.1 million in 2022 frame the typical range for EBT.
• Across the five-year window, EBT plunged 791.77% in 2022 and surged 36.48% in 2024, its largest moves.
• Tracing BJDX's EBT over 5 years: stood at -$2.5 million in 2022, then rose by 2.39% to -$2.4 million in 2023, then climbed by 12.77% to -$2.1 million in 2024, then soared by 32.53% to -$1.4 million in 2025, then sank by 41.22% to -$2.0 million in 2026.
• Business Quant data shows BJDX's EBT at -$2.0 million in Q1 2026, -$1.4 million in Q4 2025, and -$1.6 million in Q3 2025.